Compare · RXRX vs SGEN
RXRX vs SGEN
Side-by-side comparison of Recursion Pharmaceuticals Inc. (RXRX) and Seagen Inc. (SGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RXRX and SGEN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- SGEN is the larger of the two at $23.34B, about 13.3x RXRX ($1.75B).
- RXRX has hit the wire 11 times in the past 4 weeks while SGEN has been quiet.
- SGEN has more recent analyst coverage (25 ratings vs 10 for RXRX).
- Company
- Recursion Pharmaceuticals Inc.
- Seagen Inc.
- Price
- $3.30-7.56%
- $228.86-0.01%
- Market cap
- $1.75B
- $23.34B
- 1M return
- +8.73%
- -
- 1Y return
- -37.50%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2001
- News (4w)
- 11
- 0
- Recent ratings
- 10
- 25
Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Latest RXRX
- Director Borgeson Blake sold $158,500 worth of shares (40,000 units at $3.96) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 6,218,287 units (SEC Form 4)
- Director Dar Zavain was granted 5,109 shares, increasing direct ownership by 2% to 240,764 units (SEC Form 4)
- Director Li Dean Y was granted 3,747 shares, increasing direct ownership by 0.25% to 1,473,329 units (SEC Form 4)
- A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
- Director Borgeson Blake was granted 88,424 shares, increasing direct ownership by 1% to 6,258,287 units (SEC Form 4)
- Director Hershberg Robert was granted 88,424 shares, increasing direct ownership by 120% to 162,156 units (SEC Form 4)
- Director Michor Franziska was granted 88,424 shares, increasing direct ownership by 70% to 215,477 units (SEC Form 4)
- Director Sun Elaine D was granted 88,424 shares, increasing direct ownership by 186% to 135,981 units (SEC Form 4)
- Director Dar Zavain was granted 88,424 shares, increasing direct ownership by 60% to 235,655 units (SEC Form 4)
- Director Bumpus Namandje was granted 88,424 shares and sold $12,602 worth of shares (3,963 units at $3.18) as part of a pre-agreed trading plan, increasing direct ownership by 196% to 127,632 units (SEC Form 4)
Latest SGEN
- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Alltrna Announces Updates to Its Board of Directors
- Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
- How To Earn $500 A Month From Pfizer Stock
- Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
- SEC Form 15-12G filed by Seagen Inc.
- Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form SC 13D/A filed by Seagen Inc. (Amendment)
- Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)